methyl α-D-glucopyranosyl-(1->4)-α-D-glucopyranoside | 744-05-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl α-D-glucopyranosyl-(1->4)-α-D-glucopyranoside
• 英文别名: methyl α-D-maltoside；methyl-α-maltoside；methyl-(O⁴-α-D-glucopyranosyl-α-D-glucopyranoside)；Methyl-(O⁴-α-D-glucopyranosyl-α-D-glucopyranosid)；Methyl alpha-D-maltoside；(2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 744-05-8；4198-49-6；7216-69-5；7216-73-1；21973-65-9；35438-39-2；58462-71-8；66101-74-4；66101-75-5；67145-39-5；67145-40-8；70399-66-5；70427-91-7；70428-28-3；80446-84-0；81131-44-4；84129-57-7；92282-08-1；93221-82-0；114580-08-4；114817-99-1；117064-58-1；117064-59-2；118493-11-1；118493-12-2；118493-13-3；127253-90-1；127641-09-2；130192-72-2；136890-91-0；145680-83-7；146683-50-3
• 化学式: C₁₃H₂₄O₁₁
• 分子量: 356.327
• InChiKey: FHNIYFZSHCGBPP-GQMWFRSDSA-N

物化性质

• 沸点：
  648.7±55.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.2
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  179
• 氢给体数：
  7
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  methyl α-D-glucopyranosyl-(1->4)-α-D-glucopyranoside 在 吡啶 、 三乙基硅烷 、 iron (III) chloride hexahydrate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 methyl 4-O-(3-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-6-O-benzyl-α-D-glucopyranoside
  参考文献：
  名称：

  氯化铁（III）串联催化对吡喃吡喃糖苷进行一锅区域选择性保护。

  摘要：

  通过使用六水合氯化铁（III）进行串联催化可导致碳水化合物构件显示出正交的保护基团模式，如海藻糖和麦芽糖二糖的区域选择性保护所示。

  DOI：

  10.1039/c0cc04398b
• 作为产物：
  描述：

  麦芽糖 在 N-甲基吗啉 、 tetrakis(actonitrile)copper(I) hexafluorophosphate 作用下， 以 水 为溶剂， 反应 29.0h， 生成 methyl α-D-glucopyranosyl-(1->4)-α-D-glucopyranoside
  参考文献：
  名称：

  使用 4,6-二甲氧基-1,3,5-三嗪-2-基糖苷作为糖基供体的金属催化立体选择性和无保护基团合成 1,2-顺式-糖苷

  摘要：

  4,6-二甲氧基-1,3,5-triazin-2-yl 糖苷，由游离糖一步制备的糖基供体，没有羟基保护，立体选择性地等价转化为...

  DOI：

  10.1246/cl.150201

文献信息

• COMPOSITION AND METHOD FOR CANCER TREATMENT AND PREVENTION
  申请人：Liao Heather H.

  公开号：US20080261898A1

  公开（公告）日：2008-10-23

  Compounds, compositions, methods and kits are provided for treating, reducing the risk of, or preventing diseases and/or conditions, such as diseases associated with angiogenesis and/or abnormal cell proliferation, such as cancer. Compounds of the present invention have antiangiogenic and anti-cancer activity with minimum toxic effects on normal cells. Methods for preparing and manufacturing the compounds and pharmaceutical compositions are also provided.

  提供了用于治疗、减少风险或预防与血管生成和/或异常细胞增殖有关的疾病和/或疾病的化合物、组合物、方法和试剂盒，如癌症。本发明的化合物具有抗血管生成和抗癌活性，对正常细胞的毒性作用最小。还提供了制备和生产这些化合物及药物组合物的方法。
• Simple preparations of alkyl and cycloalkyl α-glycosides of maltose, cellobiose, and lactose
  作者：Shinkiti Koto、Motoko Hirooka、Takako Tashiro、Motokazu Sakashita、Masaharu Hatachi、Takayuki Kono、Miho Shimizu、Nahoko Yoshida、Sayaka Kurasawa、Natsuko Sakuma、Sunao Sawazaki、Akihiro Takeuchi、Naomi Shoya、Emi Nakamura

  DOI：10.1016/j.carres.2004.07.016

  日期：2004.10

  allyl, 4-pentenyl, and benzyl α-glycosides of maltose, cellobiose, and lactose were prepared (17–77% yield; α/β = 70/30–96/4) via a direct reaction of the free disaccharides with a binary AcBr–AcOH mixture, followed by glycosidation with alcohol using FeCl3 in MeNO2 or CH2Cl2, Zemplen deacetylation, and resolution of the anomeric mixture of glycosides by chromatography. Using MeCN as solvent for the

  摘要麦芽糖，纤维二糖和乳糖的烷基，环烷基，烯丙基，4-戊烯基和苄基α-糖苷的制备是（17-77％的收率；α/β= 70 / 30-96 / 4）。游离的二糖与二元AcBr-AcOH混合物混合，然后使用FeNO3在MeNO2或CH2Cl2中与酒精进行糖基化，Zemplen脱乙酰化，并通过色谱分离糖苷的异头混合物。使用MeCN作为糖苷化步骤的溶剂，还制备了相应的β-生物苷（16-61％产率；α/β= 25 / 75-5 / 95）。
• Spacer-modified, photolabile tetrasaccharides as analogues of maltopentaose are versatile probes for porcine pancreatic alpha-amylase
  作者：Jochen Lehmann、Lothar Ziser

  DOI：10.1016/0008-6215(92)80041-x

  日期：1992.2

  The syntheses are described of methyl 4'-O-[4-S-(3-azi-4-alpha-D-glucopyranosyloxybutyl)-6-deoxy-4 -thio-alpha-D-xylo-hex-5-enopyranosyl]-alpha-maltoside (28), methyl 4-O-[4-S-(3-azi-4-alpha-maltosyloxybutyl)-6-deoxy-4-thio- alpha-D-xylo-hex-5-enopyranosyl]-alpha-D-glucopyranoside (29), and methyl 4-S-(3-azi-4-alpha-maltotriosyloxybutyl)-6-deoxy-4-thio- alpha-D-xylo-hex-5-enopyranoside (30), which

  描述了甲基4'-O- [4-S-（3-azi-4-α-D-吡喃葡萄糖基氧基丁基）-6-脱氧-4-硫代-α-D-二甲苯基-己基-5-enopyranosyl]的合成。 -α-麦芽糖苷（28），甲基4-O- [4-S-（3-azi-4-α-麦芽糖基氧基丁基）-6-脱氧-4-硫代-α-D-木糖己基-5-烯吡喃糖基] -α-D-吡喃葡萄糖苷（29）和甲基4-S-（3-azi-4-α-麦芽三糖基氧基丁基）-6-脱氧-4-硫代-α-D-二甲苯基-六-5-烯吡喃糖苷（30） ，是麦芽五糖的类似物，其中一个中央葡糖基单元被带有光不稳定azi基的无环四元烃间隔基取代。高浓度的胰腺α-淀粉酶仅缓慢裂解30个。Ki值（mM）为0.15（28），2.1（29）和2.5（30）。在严重存在28-30的条件下，通过辐射使酶失活分别为96.4％，98.1％和40％。
• Pyrone analogs for therapeutic treatment
  申请人：Robbins Wendye

  公开号：US20100189653A1

  公开（公告）日：2010-07-29

  Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof. Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents. Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment. Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof.

  本文介绍了使用吡喃类似物或其衍生物治疗和预防代谢性疾病或其他疾病的方法。本文还介绍了使用吡喃类似物或其衍生物与一个或多个其他药剂（例如，降脂药或降糖药）联合使用治疗和预防代谢性疾病和其他疾病的方法。本文还介绍了调节脂质转运蛋白活性以增加生理隔室中脂质向外部环境排出的方法。本文所披露的方法可用于评估使用吡喃类似物或其衍生物后治疗或预防代谢性疾病的效果。
• PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT
  申请人：Lee May Dean-Ming

  公开号：US20100297020A1

  公开（公告）日：2010-11-25

  Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof. Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents. Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment. Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof.

  本文描述了通过给予吡喃类似物或其衍生物的方法来治疗和预防代谢性疾病或其他疾病。还描述了通过给予吡喃类似物或其衍生物与一个或多个额外的药物如降脂药或降糖药组合的方法来治疗和预防代谢性疾病和其他疾病。本文还描述了调节脂质转运蛋白活性以增加生理区域中脂质向外部环境的外流的方法。本文所披露的方法可用于评估在给予吡喃类似物或其衍生物后治疗或预防代谢性疾病的效果。